DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Cytomegalovirus vaccine
Cytomegalovirus vaccine
Modelling Immunization Strategies with Cytomegalovirus Vaccine Candidates
Moderna Inc Corporate Analyst Meeting on April 14, 2020 / 12:00PM
Trends in Vaccine Availability and Novel Vaccine Delivery Technologies: 2008–2025
Download Full .Pdf
Development of a Vaccine Against Human Cytomegalovirus: Advances, Barriers, and Implications for the Clinical Practice
Artículos Científicos
Recombinant Cytomegalovirus Glycoprotein B Vaccine: Rethinking the Immunological Basis of Protection Mark R
The Jordan Report 20Th Anniversary: Accelerated Development Of
Open NS Final Dissertation.Pdf
Tuberculosis Mycobacterium Vector Protects Against a Novel Murine
Limited Available Evidence Supports Theoretical Predictions of Reduced Vaccine Efficacy at Higher Exposure Dose
Structure of HCMV Glycoprotein B in the Postfusion Conformation Bound to a Neutralizing Human Antibody
The Immunological Basis for Immunization Series
Characterization of the Influences of Human Cytomegalovirus
Monitoring International Trends
Vaccines of the Future
COVID‐19 Updates for the Primary Care Doctor
Exciting Times for Cytomegalovirus (CMV) Vaccine Development: Navigating the Pathways Toward the Goal of Protecting Infants Against Congenital CMV Infection
Top View
2016 Vaccines in Development
In My View What Is the Fastest Route to a COVID-19
Morning Brew: November 30, 2020 U.S
A Phase 1 Study of 4 Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimera Vaccines in Cytomegalovirus–Seronegative Men Stuart P
2011 –2014 the Jenner Institute Is a Research Partnership Between the University of Oxford and the Pirbright Institute
Why Is Moderna Still So Pricey?
Future Vaccinations in Pregnancy
Progress, Challenges, and the Path Forward
Potential Cross-Reactive Immunity to SARS-Cov-2 from Common Human Pathogens and Vaccines
Development and Applications of Viral Vectored Vaccines to Combat Zoonotic and Emerging Public Health Threats
Cytomegalovirus Vaccine: Phase II Clinical Trial Results
Biotech/Healthcare Status Check on Development of COVID-19 Vaccines/Treatments
Antibody-Driven Design of a Human Cytomegalovirus Ghglpul128l Subunit Vaccine That Selectively Elicits Potent Neutralizing Antibodies
Global Vaccine Action Plan Monitoring, Evaluation & Accountability Secretariat Annual Report 2014 © World Health Organization 2015
An Adjuvanted Inactivated Murine Cytomegalovirus (MCMV) Vaccine
The Emerging Risks of Live Virus & Virus Vectored Vaccines
A NEWSLETTER for OHSU EMERITUS FACULTY Emeritus Faculty News Is Published Every Spring and Fall
Vaccine Research Catalog - 2016